CD4 and neoplasm: This has been compounded by a lack of reliable markers that discern tumor-specific Tregs from tumor-specific effector CD4+ T cells and self-reactive Tregs, taking us back to the drawing board due to unpredictable risks of harming peripheral tolerance.